amiodarone and carvedilol

Pharmacodynamic: additive negative chronotropic, dromotropic, and inotropic effects. Amiodarone has beta-blocking and calcium channel blocking properties; carvedilol is a beta-blocker with alpha-1 blocking activity. Pharmacokinetic: amiodarone inhibits CYP2D6, an enzyme involved in carvedilol metabolism, potentially increasing carvedilol plasma concentrations.

Patients may experience symptomatic bradycardia, heart block, hypotension, or worsening heart failure. The risk is higher in those with pre-existing conduction system disease, left ventricular dysfunction, or concurrent use of other negative chronotropic agents.

Monitor heart rate, blood pressure, and ECG at baseline and regularly during co-therapy. Use low initial doses of carvedilol and titrate cautiously. Consider alternative agents if severe bradycardia or heart block occurs. If co-prescription is necessary, ensure close follow-up.

Well-established based on pharmacodynamic and pharmacokinetic principles, supported by clinical reports and case series. Widely recognized in drug interaction databases.